DELTA-FLY-PHARMA
Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML).
Be given to ODD, Delta-Fly Pharma, Inc. can be entitled to seven extra years of marketing exclusivity and receive some benefits such as R&D rebate by getting approval.
DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed AML. A Phase 3 clinical study has been underway at MD Anderson Cancer Center in Texas and other major sites of Hematologic Cancer Treatment in USA. The company expects to complete the patients’ enrollment plan soon.
Delta-Fly Pharma, Inc. focuses not only on cancer itself but on the whole conditions of cancer patients, and aims to deliver medicines that are recommendable for cancer patients and their families.
Company profile |
|
Company name |
Delta-Fly Pharma, Inc. [Tokyo:4598] |
Capital |
3352 million Japanese Yen |
Name and Title of Representative |
Kiyoshi Eshima, PhD, President |
Date of Incorporation |
December 6, 2010 |
Description of Business |
Research and development, manufacturing and marketing of pharmaceuticals |
Head Office |
37-5, Nishikino, Miyajima, Kawauchi-cho, Tokushima 771-0116, Japan |
Branch Office |
Tokyo, Beijing, Vancouver |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206006153/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CO-ZAYO-GROUP19.4.2024 09:01:30 CEST | Press release
Zayo Group Appoints New CEO of Zayo Europe
HUBHEAD18.4.2024 22:16:32 CEST | Press release
HubHead Corp. Acquires DataSeer Inc. Assets to Expand its Vertical AI Capabilities
POPULAR,-INC.18.4.2024 20:30:30 CEST | Press release
Banco Popular Launches a New Campaign 'We Follow Your Rhythm'; Introduces Audio Branding
B2BROKER18.4.2024 18:07:28 CEST | Press release
B2Broker Increases Leverage on Major FX Pairs to 1:200
OH-PROEMION-HOLDING-GMBH18.4.2024 17:33:27 CEST | Press release
Proemion Holding GmbH Agrees to Acquire TrendMiner NV to Expand Industrial Asset-Monitoring and Analytics Platform
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom